DNA damage repair has become a hot topic in Huntington’s research. By targeting proteins involved in the repair process we might be able to slow down, or even prevent, Huntington’s disease. New research provide important insight on the DNA repair protein MSH3. In our body, we have a DNA repair protein with a fancy name: MutS Homolog 3 (MSH3). This protein…
Read more
The Italian League for Research on Huntington Disease (LIRH) hosted their annual conference in December 2020. Watch a recording of their online meeting below (in English) and get an introduction to ongoing and upcoming therapeutic studies in Huntington’s disease.
A number of researchers are using a wide range of approaches to develop new treatments for Huntington’s disease. Here is a short summary of 2020 and what to expect in 2021: After being strongly affected by Covid-19, Enroll-HD is now more or less up and running. More than 20 000 people worldwide are participating in Enroll-HD,…
Read more
Join our last webinar in 2020! Together with Prof. Anne Rosser, Dr. Ralf Reilmann and Dr. Alzbeta Mühlbäck we will take a look at recent achievements in drug development and make some predictions for 2021! WHEN? 16. December (Today) 19:00 Central European Time20:00 Portugal, England18:00 Finland, Greece More information and registration here.
Two days ago, PTC Therapeutics announced that the drug candidate PTC518 has entered into a “Phase 1 Clinical Trial”. The initial results are expected in the first half of 2021. PTC518 is an orally bioavailable molecule. In other words, the drug candidate is administered in the form of a pill taken through the mouth. In…
Read more
The HD Insights Podcast by the Huntington Study Group is an interview series with the people working in Huntington’s disease research and treatments. The Huntington Study Group is a non-profit research organisation formed in 1993 – the same year as the Huntington’s disease (HD) gene was discovered. Learn more: The Insight Podcast The group is dedicated…
Read more
Join webinars, get updated on the latest research and learn more about our new project Moving Forward! Read our Autumn Newsletter! Click here.
DOMINO-HD is a European study funded by the EU Joint Programme for Neurodegenerative Disease. The aim of the study is to investigate the relationship between genetic and lifestyle factors and Huntington’s disease symptom progression. Written by Dr. Cheney Drew Research has shown that the rate of decline in people with Huntington’s disease (HD) can be…
Read more
We are launching “Moving Forward”. The new project aims at including people from Huntington’s disease families in drug development by facilitating an active and long-lasting commitment from patients and family members. Written by Filipa Júlio, Project Manager in Moving Forward Between September 2016 and December 2019, the European Huntington Association (EHA) has run multiple European and…
Read more
The Swiss pharmaceutical company Novartis is currently developing a pill for Huntington’s disease. Two days ago, the US Food and Drug Administration, FDA, granted an Orphan Drug Designation for the drug. The drug is called branaplam (LMI070) and is administered in the form of a pill that you take through your mouth. At the moment,…
Read more
